促性腺激素释放激素类似物治疗对中枢性性早熟和快速进展型青春期患儿成年终身高改善的Meta分析

目的 系统评价促性腺激素释放激素类似物（gonadotropin-releasing hormone analogue，GnRHa）治疗6岁以上中枢性性早熟（central precocious puberty，CPP）和快速进展型青春期（early and fast puberty，EFP）患儿的疗效。 方法 检索PubMed、MEDLINE、Embase、Cochrane Library、中国知网和万方数据库，收集GnRHa治疗CPP和EFP患儿的相关文献，应用Stata 12.0软件对文献资料进行Meta分析。 结果 共纳入10篇文献。总样本量为720例，其中GnRHa治疗组475例，对照组245例。Meta分析结果显示GnRHa治疗组成年终身高［加权均数差（weighted mean difference，WMD）=3.30，95%CI：2.49~4.12，P<0.001］、成年终身高标准差积分（WMD=0.51，95%CI：0.29~0.73，P<0.001）、身高获益（WMD=2.89，95%CI：2.17~3.60，P<0.001）均优于对照组。所有的研究均无严重不良事件报道。 结论 GnRHa治疗对于改善6岁以上CPP和EFP患儿的成年终身高安全有效。 引用格式:

Effect of gonadotropin-releasing hormone analogue treatment in improving final adult height of children with central precocious puberty or early and fast puberty: a Meta analysis

Objective To systematically evaluate the effect of gonadotropin-releasing hormone analogue (GnRHa) treatment on the final adult height of children over 6 years of age with central precocious puberty (CPP) or early and fast puberty (EFP). Methods PubMed, MEDLINE, Embase, Cochrane Library, CNKI, and Wanfang Data were searched for related articles on GnRHa treatment for children with CPP or EFP. Stata 12.0 software was used to perform a Meta analysis of related data. Results A total of 10 studies were included, and the total sample size was 720 children, with 475 children in the GnRHa treatment group and 245 children in the control group. The Meta analysis showed that compared with the control group, the GnRHa treatment group had significantly better final adult height (WMD=3.30, 95%CI: 2.49-4.12, P<0.001), standard deviation score of final adult height (WMD=0.51, 95%CI: 0.29-0.73, P<0.001), and height gain (WMD=2.89, 95%CI: 2.17-3.60, P<0.001). No severe adverse events were reported in these studies. Conclusions GnRHa treatment is safe and effective in improving the final adult height of children over 6 years of age with CPP or EFP. Citation: